|
|
Volumn 49, Issue 4, 2001, Pages 937-946
|
|
Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
a b a c d e f g
b
RTOG
(United States)
|
|
Author keywords
Androgen suppression; Carcinoma of the prostate; RTOG Trial 85 31
|
|
Indexed keywords
ACID PHOSPHATASE;
GONADORELIN DERIVATIVE;
GOSERELIN;
PROSTATE SPECIFIC ANTIGEN;
ARTICLE;
BEAM THERAPY;
CANCER STAGING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
HUMAN;
LYMPH NODE METASTASIS;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CARCINOMA;
RECURRENT DISEASE;
STATISTICAL ANALYSIS;
SURVIVAL;
TREATMENT OUTCOME;
ANDROGEN ANTAGONISTS;
ANTINEOPLASTIC AGENTS, HORMONAL;
CHEMOTHERAPY, ADJUVANT;
DISEASE-FREE SURVIVAL;
FOLLOW-UP STUDIES;
GOSERELIN;
HUMANS;
MALE;
NEOPLASM STAGING;
PROGNOSIS;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATECTOMY;
PROSTATIC NEOPLASMS;
RADIOTHERAPY DOSAGE;
SURVIVAL ANALYSIS;
TREATMENT FAILURE;
|
|
EID: 0035869725
PISSN: 03603016
EISSN: None
Source Type: Journal
DOI: 10.1016/S0360-3016(00)01516-9 Document Type: Article |
|
Times cited : (371)
|
|
References (14)
|
